TPD

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 8, 2024

WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 (KT-621) and TYK2 (KT-294) are being presented in the poster session at the American Academy of Dermatology’s Annual Meeting in San Diego, California. Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents. Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting. Based on the results generated to date, Kymera intends to initiate Phase 1 testing for KT-621 and KT-294 in the in the second half of 2024 and the first half of 2025, respectively. Data from both Phase 1 trials are expected to be reported in 2025.

Key Points: 
  • Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents.
  • Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting.
  • “Our differentiated strategy to targeted protein degradation has resulted in an industry-leading immunology pipeline of oral degrader medicines, each with the potential to treat multiple complex immuno-inflammatory diseases.
  • At low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated.

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Retrieved on: 
Wednesday, February 28, 2024

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Key Points: 
  • WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
    TD Cowen 44th Annual Healthcare Conference in Boston, MA on March 6 at 12:50 p.m.
  • ET;
    Leerink Partners Global Biopharma Conference in Miami, FL on March 12 at 3:40 p.m.
  • Live webcasts of the presentations will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com.
  • A replay of the webcasts will be archived and available following the events.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 22, 2024

Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.

Key Points: 
  • Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.
  • Enrollment in both trials is ongoing, with topline data expected to be reported in the first half of 2025.
  • Kymera unveiled its first-in-class oral STAT6 degrader, KT-621, at its Immunology R&D Day in January.
  • To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

Retrieved on: 
Thursday, February 15, 2024

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m.

Key Points: 
  • WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m.
  • To access the February 22 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.
  • A live webcast of the Company’s conference call will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com.
  • A replay of the webcast will be archived and available following the event.

SK Life Science Labs Experts Unveil Latest Scientific Findings at Keystone Symposia on Epigenetic Mechanisms and Cancer Treatment, and the 2nd Annual Molecular Glue Drug Development Summit

Retrieved on: 
Thursday, February 8, 2024

Helai Mohammad, Ph.D., VP and Head of Biology, and one of the expert scientists leading SK Life Science Labs, whose leadership team together have more than 120 years of drug discovery and development experience, was invited to present at the Keystone Symposia.

Key Points: 
  • Helai Mohammad, Ph.D., VP and Head of Biology, and one of the expert scientists leading SK Life Science Labs, whose leadership team together have more than 120 years of drug discovery and development experience, was invited to present at the Keystone Symposia.
  • Dr. Mohammad showcased SK Life Science Labs’ most recent data and its novel approach to the degradation of epigenetic machinery for the treatment of cancer.
  • “The pre-clinical data we presented at the Keystone Symposia broadens our understanding of how targeted protein degradation can be leveraged to achieve selectivity and, thereby, increase efficacy,” said Dr. Mohammad.
  • For more information about SK Life Science Labs and to review these and other scientific presentations, please visit our website at www.sklslabs.com/news-media .

Plug Cryogenic Trailers Leave Tennessee Hydrogen Production Plant for Customer Deliveries

Retrieved on: 
Thursday, February 8, 2024

LATHAM, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, announces that Plug cryogenic trailers filled with liquid hydrogen are being deployed from its recently commissioned Tennessee hydrogen production plant for customer deliveries. The achievement comes two days following the official commencement of operations at the Charleston, TN production plant and is already servicing east coast pedestal customers, including Walmart, Home Depot and others.

Key Points: 
  • Plug cryogenic trailers have been filled with liquid hydrogen for delivery at east coast pedestal customer sites - two days following commencement of operations.
  • Between Georgia and Tennessee, Plug now has about 25 tons per day of liquid hydrogen production capacity, further enhancing the overall generation network in the US.
  • LATHAM, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, announces that Plug cryogenic trailers filled with liquid hydrogen are being deployed from its recently commissioned Tennessee hydrogen production plant for customer deliveries.
  • In addition to the 10 TPD plant in Tennessee, Plug began production of liquid green hydrogen at its Georgia plant on January 23, 2024.

Plug Power Starts Production of Liquid Hydrogen at its Existing Tennessee Plant

Retrieved on: 
Tuesday, February 6, 2024

LATHAM, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has re-started operation of its hydrogen plant in Charleston, Tennessee, adding about ten tons per day (TPD) of liquid hydrogen supply back onto the U.S. market. Plug also implemented design improvements to enhance overall plant efficiency.

Key Points: 
  • Between Georgia and Tennessee, Plug now has about 25 tons per day of liquid hydrogen production capacity, further enhancing the overall generation network in the US
    LATHAM, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has re-started operation of its hydrogen plant in Charleston, Tennessee, adding about ten tons per day (TPD) of liquid hydrogen supply back onto the U.S. market.
  • Plug’s cryogenic trailer fleet will deliver liquid hydrogen from the Tennessee plant to Plug’s pedestal customers throughout North America, with a high-density of users clustered throughout the Midwest and along the East Coast.
  • “With the Tennessee plant coming back online, we have taken another step towards building a vertically integrated hydrogen network in North America,” said Andy Marsh, Plug Power CEO.
  • Plug began production of liquid green hydrogen at its Georgia plant on January 23, 2024.

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

Retrieved on: 
Wednesday, January 31, 2024

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m.

Key Points: 
  • WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m.
  • ET.
  • A live webcast of the fireside chat will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com.
  • A replay of the webcast will be archived and available following the event.

FEELM Introduces the World's First Burst Power Ceramic Coil Vape Solution - 0.5 Sec to Feel the Burst of Flavors

Retrieved on: 
Thursday, February 1, 2024

LAS VEGAS, Feb. 1, 2024 /PRNewswire/ -- FEELM, the world's leading vape solution provider, announced the launch of the world's first burst power ceramic coil vape solution – FEELM TURBO.

Key Points: 
  • LAS VEGAS, Feb. 1, 2024 /PRNewswire/ -- FEELM, the world's leading vape solution provider, announced the launch of the world's first burst power ceramic coil vape solution – FEELM TURBO.
  • Full Blast in 0.5 Sec: Enjoy the Best in Every Puff
    What is the good quality of high burst power?
  • FEELM, a leader in ceramic coil technology, has dedicated their expertise to developing a dedicated burst power ceramic coil solution.
  • One of the burst power ceramic coil performs more than on par with dual MESH coils.

Lion One Provides Update on Tuvatu Operations in Fiji, Grants Options

Retrieved on: 
Thursday, January 18, 2024

Lion One Metals' Chairman and CEO Walter Berukoff stated: "2023 was a year of noteworthy accomplishments for Lion One Metals.

Key Points: 
  • Lion One Metals' Chairman and CEO Walter Berukoff stated: "2023 was a year of noteworthy accomplishments for Lion One Metals.
  • The goal for 2024 is to have the 500 TPD processing plant in operation by the end of Q3.
  • A significant portion of the material mined during the 300 TPD pilot plant phase of operations is therefore expected to be development material.
  • The stock options are exercisable at $1.00 per share and expire 5 years from the date of grant.